目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SCOPE
1.4 INCLUSIONS & EXCLUSIONS
1.5 YEARS CONSIDERED
1.6 CURRENCY CONSIDERED
1.7 KEY STAKEHOLDERS
1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentation of companies and primary interviews
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ASSESSMENT
2.5 RESEARCH ASSUMPTIONS
2.5.1 PARAMETRIC ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030
4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030
4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030
4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030
4.7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2025 VS. 2030
4.8 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030
4.9 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030
4.10 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
5.2.1.2 Growing R&D funding
5.2.1.3 Surge in technological advancements
5.2.1.4 Rising use of point-of-care diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Inadequate reimbursements
5.2.2.2 High cost of molecular diagnostic instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics
5.2.3.2 Increasing growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers and labor shortage
5.2.4.3 Introduction of alternative technologies
5.3 PRICING ANALYSIS
5.3.1 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS
5.3.2 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER
5.3.3 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION
5.4 PATENT ANALYSIS
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 HS CODES
5.7.1 IMPORT SCENARIO (HS CODE 3822)
5.7.2 EXPORT SCENARIO (HS CODE 3822)
5.8 ECOSYSTEM ANALYSIS
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT FROM NEW ENTRANTS
5.9.2 THREAT FROM SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY FRAMEWORK
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.2.1 Germany
5.10.1.2.2 UK
5.10.1.2.3 France
5.10.1.2.4 Italy
5.10.1.3 Asia Pacific
5.10.1.3.1 China
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.4.2 Mexico
5.10.1.5 Middle East
5.10.1.5.1 Africa
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Polymerase chain reaction
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Microarrays
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Next-generation sequencing
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
5.16.2 CASE STUDY 2: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS AND BED MANAGEMENT
5.16.3 CASE STUDY 3: RAPID PCR TESTING STREAMLINED EMERGENCY CARE AND SURGICAL RESOURCE MANAGEMENT IN GERMAN HOSPITAL
5.17 IMPACT OF AI/GENERATIVE AI ON MOLECULAR DIAGNOSTICS MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI
5.17.2.1 Key use cases
5.17.3 IMPLEMENTATION OF AI BY KEY COMPANIES
5.17.4 FUTURE OF AI IN MOLECULAR DIAGNOSTICS MARKET
5.18 US 2025 TARIFF
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Hospitals & clinics
5.18.5.2 Diagnostic laboratories

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 REAGENTS & KITS
6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION TO PROPEL MARKET
6.3 INSTRUMENTS
6.3.1 RISING NEED FOR QUICK AND ACCURATE TEST RESULTS TO BOOST MARKET
6.4 SERVICES & SOFTWARE
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE
7.1 INTRODUCTION
7.2 LAB TESTS
7.2.1 INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET
7.3 POC TESTS
7.3.1 INCREASED INVESTMENT BY PUBLIC HEALTH AGENCIES AND GOVERNMENTS TO BOOST MARKET

8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE
8.1 INTRODUCTION
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET
8.3 URINE
8.3.1 NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET
8.4 OTHER SAMPLE TYPES

9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 POLYMERASE CHAIN REACTION
9.2.1 RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH
9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
9.3.1 NEED FOR PROMPT DIAGNOSIS TO STIMULATE GROWTH
9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
9.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
9.5 IN SITU HYBRIDIZATION
9.5.1 RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES AND GENE MAPPING TO BOOST MARKET
9.6 DNA MICROARRAYS
9.6.1 SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET
9.7 OTHER TECHNOLOGIES

10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 INFECTIOUS DISEASE DIAGNOSTICS
10.2.1 SEXUALLY TRANSMITTED DISEASES
10.2.1.1 CT/NG
10.2.1.1.1 Growing development of novel assays to boost market
10.2.1.2 HIV
10.2.1.2.1 Increasing blood transfusions and blood donations to propel market
10.2.1.3 HPV
10.2.1.3.1 Rising cases of cervical cancer to augment growth
10.2.1.4 Syphilis
10.2.1.4.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
10.2.1.5 Other sexually transmitted diseases
10.2.2 HEPATITIS
10.2.2.1 Hepatitis B
10.2.2.1.1 Need for ongoing management and monitoring of virus to drive market
10.2.2.2 Hepatitis C
10.2.2.2.1 Favorable government initiatives to support growth
10.2.2.3 Other hepatitis diseases
10.2.3 RESPIRATORY INFECTIOUS DISEASES
10.2.3.1 Tuberculosis
10.2.3.1.1 Rising focus on reducing tuberculosis deaths to fuel market
10.2.3.2 Influenza
10.2.3.2.1 Growing strains and subtypes to drive market
10.2.3.3 Pharyngitis
10.2.3.3.1 Need to differentiate between bacterial and viral infections to fuel growth
10.2.3.4 Other respiratory infectious diseases
10.2.4 HOSPITAL-ACQUIRED INFECTIONS
10.2.4.1 Booming geriatric population to aid growth
10.2.5 VECTOR-BORNE DISEASES
10.2.5.1 Growing focus on disease surveillance to propel market
10.2.6 OTHER INFECTIOUS DISEASES
10.3 ONCOLOGY TESTING
10.3.1 BREAST CANCER
10.3.1.1 Increasing need to improve survival rates to support growth
10.3.2 COLORECTAL CANCER
10.3.2.1 Rising demand for biomarkers to fuel market
10.3.3 LUNG CANCER
10.3.3.1 Increasing use of predictive biomarkers to drive market
10.3.4 PROSTATE CANCER
10.3.4.1 Surge in advancements in genomic technologies to aid growth
10.3.5 OTHER CANCER TYPES
10.4 GENETIC TESTING
10.4.1 GROWING IMPORTANCE OF DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET
10.5 OTHER APPLICATIONS

11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
11.1 INTRODUCTION
11.2 MULTIPLEX TESTING
11.2.1 RISING DEMAND FOR QUICK DIAGNOSIS TO PROMOTE GROWTH
11.3 SINGLEPLEX TESTING
11.3.1 NEED FOR AFFORDABLE TESTING TO AUGMENT GROWTH

12 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION
12.1 INTRODUCTION
12.2 DIAGNOSTIC
12.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING AND TIMELY TREATMENT TO DRIVE MARKET
12.3 SCREENING
12.3.1 GROWING IMPORTANCE OF EARLY INFECTIOUS DISEASE SCREENING TO PROPEL MARKET EXPANSION

13 MOLECULAR DIAGNOSTICS MARKET, BY END USER
13.1 INTRODUCTION
13.2 DIAGNOSTIC LABORATORIES
13.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH
13.3 HOSPITALS & CLINICS
13.3.1 GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH
13.4 OTHER END USERS

14 MOLECULAR DIAGNOSTICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK
14.2.2 US
14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market
14.2.3 CANADA
14.2.3.1 Growing focus on genomic research to fuel market
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK
14.3.2 GERMANY
14.3.2.1 Robust healthcare spending and increasing per capita disposable income to propel market
14.3.3 UK
14.3.3.1 Expanding community-based diagnostics to drive adoption of molecular diagnostics
14.3.4 FRANCE
14.3.4.1 Rising R&D expenditure for product launches and development of new technologies to augment growth
14.3.5 ITALY
14.3.5.1 Growing demographic shift toward elderly population to support market
14.3.6 SPAIN
14.3.6.1 Surge in demand for genetic and prenatal testing to aid growth
14.3.7 RUSSIA
14.3.7.1 Increasing access to quality healthcare to boost market growth
14.3.8 SWITZERLAND
14.3.8.1 Rising healthcare spending for new medications and therapies to drive market
14.3.9 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK
14.4.2 CHINA
14.4.2.1 Growing public access to modern healthcare to drive market
14.4.3 JAPAN
14.4.3.1 Universal healthcare reimbursement policy to support market
14.4.4 INDIA
14.4.4.1 Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market
14.4.5 AUSTRALIA
14.4.5.1 Rising technological advancements to stimulate growth
14.4.6 SOUTH KOREA
14.4.6.1 Favorable government initiatives for promoting medical tourism to support growth
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK
14.5.2 BRAZIL
14.5.2.1 Universal healthcare access to drive adoption in Brazil
14.5.3 MEXICO
14.5.3.1 Booming medical tourism industry to aid growth
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MACROECONOMIC OUTLOOK
14.6.2 SAUDI ARABIA
14.6.2.1 Rising government healthcare expenditure to boost market
14.6.3 UAE
14.6.3.1 Improvements in healthcare infrastructure to support growth
14.6.4 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
15.3 REVENUE SHARE ANALYSIS
15.4 MARKET SHARE ANALYSIS, 2024
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
15.5.5.1 Company footprint
15.5.5.2 Region footprint
15.5.5.3 Product & service footprint
15.5.5.4 Sample type footprint
15.5.5.5 Application footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
15.6.5.1 Detailed list of key startups/SMES
15.6.5.2 Competitive benchmarking of startups/SMES
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT/SERVICES LAUNCHES AND APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS

16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 DANAHER CORPORATION
16.1.1.1 Business overview
16.1.1.2 Products/Services offered
16.1.1.3 Recent developments
16.1.1.3.1 Product/Service launches and approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 F. HOFFMANN-LA ROCHE LTD
16.1.2.1 Business overview
16.1.2.2 Products/Services offered
16.1.2.3 Recent developments
16.1.2.3.1 Product/Service launches and approvals
16.1.2.3.2 Deals
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 ILLUMINA, INC.
16.1.3.1 Business overview
16.1.3.2 Products/Services offered
16.1.3.3 Recent developments
16.1.3.3.1 Product/Service launches and approvals
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 HOLOGIC, INC.
16.1.4.1 Business overview
16.1.4.2 Products/Services offered
16.1.4.3 Recent developments
16.1.4.3.1 Product/Service launches and approvals
16.1.4.3.2 Deals
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 BIOMERIEUX
16.1.5.1 Business overview
16.1.5.2 Products/Services offered
16.1.5.3 Recent developments
16.1.5.3.1 Product/Service launches and approvals
16.1.5.3.2 Deals
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 ABBOTT LABORATORIES
16.1.6.1 Business overview
16.1.6.2 Products/Services offered
16.1.6.3 Recent developments
16.1.6.3.1 Product/Service launches and approvals
16.1.6.3.2 Deals
16.1.7 THERMO FISHER SCIENTIFIC INC.
16.1.7.1 Business overview
16.1.7.2 Products/Services offered
16.1.7.3 Recent developments
16.1.7.3.1 Product/Service launches and approvals
16.1.7.3.2 Deals
16.1.8 QIAGEN N.V.
16.1.8.1 Business overview
16.1.8.2 Products/Services offered
16.1.8.3 Recent developments
16.1.8.3.1 Product/Service launches and approvals
16.1.8.3.2 Deals
16.1.8.3.3 Expansions
16.1.9 REVVITY, INC.
16.1.9.1 Business overview
16.1.9.2 Products/Services offered
16.1.10 MYRIAD GENETICS, INC.
16.1.10.1 Business overview
16.1.10.2 Products/Services offered
16.1.10.3 Recent developments
16.1.10.3.1 Product/Service launches and approvals
16.1.10.3.2 Deals
16.1.11 SIEMENS HEALTHINEERS AG
16.1.11.1 Business overview
16.1.11.2 Products/Services offered
16.1.11.3 Recent developments
16.1.11.3.1 Product/Service launches and approvals
16.1.11.3.2 Deals
16.1.11.3.3 Expansions
16.2 OTHER PLAYERS
16.2.1 BECTON, DICKINSON AND COMPANY (BD)
16.2.2 GRIFOLS, S.A.
16.2.3 QUIDELORTHO CORPORATION
16.2.4 DIASORIN S.P.A.
16.2.5 EXACT SCIENCES CORPORATION
16.2.6 GENETIC SIGNATURES
16.2.7 AGILENT TECHNOLOGIES, INC.
16.2.8 MDXHEALTH
16.2.9 BIOCARTIS
16.2.10 MEDIGEN BIOTECHNOLOGY CORP.
16.2.11 VELA DIAGNOSTICS
16.2.12 AMOY DIAGNOSTICS CO., LTD.
16.2.13 BRUKER CORPORATION (ELITECHGROUP)
16.2.14 MOLBIO DIAGNOSTICS LIMITED
16.2.15 GENEOMBIOTECHNOLOGIES
16.2.16 SAVYON DIAGNOSTICS
16.2.17 UNIOGEN OY

17 APPENDIX
17.1 DISCUSSION GUIDE
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
17.3 CUSTOMIZATION OPTIONS
17.4 RELATED REPORTS
17.5 AUTHOR DETAILS